Your browser doesn't support javascript.
loading
Two Novel GLDC Mutations in a Neonate with Nonketotic Hyperglycinemia.
Nickerson, Sarah L; Balasubramaniam, Shanti; Dryland, Philippa A; Love, Jennifer M; Kava, Maina P; Love, Donald R; Prosser, Debra O.
Afiliación
  • Nickerson SL; Diagnostic Genetics, LabPLUS, Auckland City Hospital, Auckland, New Zealand.
  • Balasubramaniam S; Metabolic Unit, Department of Rheumatology/Metabolic Medicine, Princess Margaret Hospital, Perth, WA, Australia; School of Paediatrics and Child Health, University of Western Australia, WA, Australia.
  • Dryland PA; Diagnostic Genetics, LabPLUS, Auckland City Hospital, Auckland, New Zealand.
  • Love JM; Diagnostic Genetics, LabPLUS, Auckland City Hospital, Auckland, New Zealand.
  • Kava MP; School of Paediatrics and Child Health, University of Western Australia, WA, Australia; Department of Paediatric Neurology, Princess Margaret Hospital for Children, Perth, WA, Australia.
  • Love DR; Diagnostic Genetics, LabPLUS, Auckland City Hospital, Auckland, New Zealand.
  • Prosser DO; Diagnostic Genetics, LabPLUS, Auckland City Hospital, Auckland, New Zealand.
J Pediatr Genet ; 5(3): 174-80, 2016 Sep.
Article en En | MEDLINE | ID: mdl-27617160
ABSTRACT
Nonketotic hyperglycinemia, also known as glycine encephalopathy (OMIM #605899), is an autosomal recessive disorder of glycine metabolism resulting from a defect in the glycine cleavage system. We report two novel mutations of the glycine decarboxylase (GLDC) gene observed in a compound heterozygous state in a neonate of mixed Maori and Caucasian parentage c.395C>T p.(Ser132Leu) in exon 3, and c.256-?_334+?del p.(Ser86Valfs*119), resulting in an out-of-frame deletion of exon 2. Additionally, we describe our experience of implementing the ketogenic diet, alongside standard pharmacological therapy, and highlight its potential therapeutic benefit in severe nonketotic hyperglycinemia, particularly in seizure management.
Palabras clave